[2] . Interferon free therapy has recently become available and preliminary studies show 70% SVR in post transplant patients [3] . Since genotype 3 has a high response to pegylated Interferon 3, it remains a competitive agent Aims and Methods: The aim of this study was to determine the efficacy of pegylated interferon plus ribavirin in the treatment of recurrent hepatitis C following liver transplantation.15 patients with recurrent hepatitis C following liver transplantation were included in the study, 13 males and 2 females. Mean age was 52 years.13 had genotype 3 disease, one genotype 2 and one genotype 1.11 were living donor and 4 were cadaveric grafts.13 were on tacrolimus and MMF, one on tacrolimus alone and one on cyclosporine and MMF.6 patients were treated within 2 years of transplant and remaining 9 were treated 3-5 years after transplant. Liver biopsy was done prior to therapy in 6 patients. All patients received pegylated interferon a2a 180 g weekly plus ribavirin 15mg/kg daily for 48 weeks Results: 14 out of 15 patients [93.3%] achieved SVR. This included all 13 Genotype 3 patients [100%] and the single genotype 2 patient. One patient, genotype 1, was nonresponder to treatment. Treatment was stopped at 22 and 36 weeks in 2 patients due to anaemia. Both achieved SVR.11 patients were administered erythropoietin for anemia.7 patients required ribavirin dose reduction for anemia, and achieved SVR despite dose reduction